688065 凯赛生物
交易中 09-29 09:30:44
资讯
新帖
简况
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
证券之星 · 09-28 03:45
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
凯赛生物（688065）披露2025年员工持股计划预留份额分配公告，9月24日股价下跌2.49%
证券之星 · 09-24
凯赛生物（688065）披露2025年员工持股计划预留份额分配公告，9月24日股价下跌2.49%
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
证券之星 · 09-24
股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》
凯赛生物：目前合肥复材项目的部分生产线进入设备调试阶段
证券之星 · 09-21
凯赛生物：目前合肥复材项目的部分生产线进入设备调试阶段
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
证券之星 · 09-21
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
凯赛生物：公司与招商局集团的合作在稳步推进中
证券之星 · 09-21
凯赛生物：公司与招商局集团的合作在稳步推进中
凯赛生物：公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势
证券之星 · 09-21
凯赛生物：公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势
凯赛生物：2026年上半年生物基聚酰胺系列营收1.08亿元，同比增长63%
证券之星 · 09-21
凯赛生物：2026年上半年生物基聚酰胺系列营收1.08亿元，同比增长63%
破发股凯赛生物跌4.97% A股共募115亿IPO中信证券保荐
中金财经 · 09-14
破发股凯赛生物跌4.97% A股共募115亿IPO中信证券保荐
9月11日凯赛生物现3笔大宗交易 机构净卖出4368.65万元
证券之星 · 09-11
9月11日凯赛生物现3笔大宗交易 机构净卖出4368.65万元
【私募调研记录】勤远投资调研凯赛生物
证券之星 · 09-11
【私募调研记录】勤远投资调研凯赛生物
股市必读：凯赛生物新发布《中信证券股份有限公司关于上海凯赛生物技术股份有限公司2026年半年度持续督导跟踪报告》
证券之星 · 09-11
股市必读：凯赛生物新发布《中信证券股份有限公司关于上海凯赛生物技术股份有限公司2026年半年度持续督导跟踪报告》
凯赛生物：9月9日接受机构调研，兴业证券、浙商证券资管等多家机构参与
证券之星 · 09-10
凯赛生物：9月9日接受机构调研，兴业证券、浙商证券资管等多家机构参与
凯赛生物被调出科创50指数 A股共募115亿IPO中信证券保荐
中金财经 · 09-01
凯赛生物被调出科创50指数 A股共募115亿IPO中信证券保荐
每周股票复盘：凯赛生物（688065）股东拟减持不超2%股份
证券之星 · 08-30
每周股票复盘：凯赛生物（688065）股东拟减持不超2%股份
破发股凯赛生物股东拟减持 A股募115亿IPO中信证券保荐
中金财经 · 08-25
破发股凯赛生物股东拟减持 A股募115亿IPO中信证券保荐
凯赛生物（688065）披露持股5%以上股东减持股份计划公告，8月24日股价下跌2.81%
证券之星 · 08-24
凯赛生物（688065）披露持股5%以上股东减持股份计划公告，8月24日股价下跌2.81%
凯赛生物公告：股东拟于9月15日至12月14日期间减持不超2%股份
美股速递 · 08-24
凯赛生物公告：股东拟于9月15日至12月14日期间减持不超2%股份
每周股票复盘：凯赛生物（688065）Q2净利增20.56%
证券之星 · 08-23
每周股票复盘：凯赛生物（688065）Q2净利增20.56%
股市必读：凯赛生物中报 - 第二季度单季净利润同比增长20.56%
证券之星 · 08-21
股市必读：凯赛生物中报 - 第二季度单季净利润同比增长20.56%
加载更多
公司概况
公司名称：
上海凯赛生物技术股份有限公司
所属行业：
化学纤维制造业
上市日期：
2020-08-12
主营业务：
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC9-DC18）及其衍生产品、生物基戊二胺、系列生物基聚酰胺树脂及其改性产品、生物基连续纤维热塑型复合材料（Bio-PPACFRT）、生物基哌啶。
发行价格：
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":38.15,"timestamp":1790645444000,"preClose":38.15,"halted":0,"volume":40839,"delay":0,"changeRate":0,"floatShares":583000000,"shares":721000000,"eps":0.8663,"marketStatus":"交易中","change":0,"latestTime":"09-29 09:30:44","open":38.17,"high":38.26,"low":37.92,"amount":1557400,"amplitude":0.0089,"askPrice":38.15,"askSize":6,"bidPrice":38.08,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.8663,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1790652600000},"marketStatusCode":2,"adr":0,"adjPreClose":38.15,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790645400000,1790652600000],[1790658000000,1790665200000]],"highLimit":41.97,"lowLimit":34.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":1.55,"roa":"--","peRate":44.037862,"roe":"2.08%","epsLYR":0.82,"committee":-0.2,"marketValue":27517000000,"turnoverRate":0.0001,"status":2,"floatMarketCap":22256000000},"requestUrl":"/m/hq/s/688065/","defaultTab":"news","newsList":[{"id":"2670401147","title":"股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401147?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:45","pubTimestamp":1790538314,"startTime":"0","endTime":"0","summary":"关于2025年员工持股计划预留份额分配的公告上海凯赛生物技术股份有限公司同意将15.00万股预留份额授予不超过54名激励对象，认购价格为25.08元/股；预留份额分配后，员工持股计划所持股票总数不超过公司股本总额的10%，单个持有人对应股票总数不超过公司股本总额的1%；标的股票自过户至员工持股计划名下之日起12个月后分两批解锁，每批解锁50%，解锁需满足公司、部门及个人层面业绩考核要求；该事项无需提交股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469419","title":"凯赛生物（688065）披露2025年员工持股计划预留份额分配公告，9月24日股价下跌2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469419","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469419?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:48","pubTimestamp":1790243336,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，凯赛生物报收于38.34元，较前一交易日下跌2.49%，最新总市值为276.54亿元。凯赛生物近日披露《关于2025年员工持股计划预留份额分配的公告》。公告显示，公司于2026年9月23日召开相关会议，审议通过《关于2025年员工持股计划预留份额分配的议案》，同意将15.00万股预留份额授予不超过54名激励对象，认购价格为25.08元/股。标的股票自过户至员工持股计划名下之日起12个月后分两批解锁，每批解锁50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400031254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438580","title":"股市必读：凯赛生物新发布《第三届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669438580?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:10","pubTimestamp":1790183420,"startTime":"0","endTime":"0","summary":"关于非全资控股子公司之间提供担保额度的公告上海凯赛生物技术股份有限公司授权其在总额不超过20亿元额度内向非全资控股子公司提供担保，被担保人为凯赛（太原）生物材料有限公司和凯赛（太原）生物科技有限公司，二者均为公司合并报表范围内控股子公司，资产负债率均未超过70%；本次担保无需提交股东大会审议，额度可在两家子公司间调剂；截至公告日，公司及其控股子公司对外担保总额为3亿元，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400001915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669915551","title":"凯赛生物：目前合肥复材项目的部分生产线进入设备调试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669915551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669915551?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976218,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好，关注到公司合肥年产4万吨碳纤维增强生物基聚酰胺复合材料项目计划今年年内建成。请问目前项目进度如何？能否按期投产？投产后主要面向哪些行业和客户？谢谢！凯赛生物回复：尊敬的投资者，您好。目前合肥复材项目的部分生产线进入设备调试阶段，产品下游涵盖新能源、建筑、物流等行业。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669553961","title":"凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2669553961","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669553961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976217,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好，太原年产50万吨戊二胺和90万吨聚酰胺项目之前公告延期到了2027年底。公司年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中，具体进展请参考公司公告。山西科创城投作为公司的早期外部投资者，其减持系基于自身资金需求，不影响公司与园区的项目建设。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669553691","title":"凯赛生物：公司与招商局集团的合作在稳步推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2669553691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669553691?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976216,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物09月21日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669578155","title":"凯赛生物：公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2669578155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669578155?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976212,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司介绍配套长安凯程无人物流车的复合地板具有不少实用的性能。问题一：该地板能同时提供给其他客户吗？问题二：量产后，与传统材料相比，性价比情况如何？或者说后续降本空间大吗？凯赛生物回复：尊敬的投资者，您好。公司生物基聚酰胺复合材料地板产品具备耐磨、轻量化、低碳的综合优势，可以推广应用于其他主机厂的类似场景。目前，公司商务团队正在积极拓展客户，扩大产品应用范围。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669515552","title":"凯赛生物：2026年上半年生物基聚酰胺系列营收1.08亿元，同比增长63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669515552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669515552?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976211,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司上市后投入的生物基聚酰胺产品，10万吨自投产后毛利率下滑到负1X%，销量年年下滑。2026年上半年，公司生物基聚酰胺系列实现营业收入1.08亿元，同比增长63%,毛利率0.57%。目前，公司的系列生物基聚酰胺及其复合材料产品处于商业化推广阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656273","title":"破发股凯赛生物跌4.97% A股共募115亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656273","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667656273?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:01","pubTimestamp":1789372863,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 凯赛生物 今日收报37.88元，跌幅4.97%。该股目前处于破发状态。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物上述2次募集资金合计114.87亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260914/32369019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1820825898.SGD","KCE","BK0028","600030","83130","BK0196","LU1997245094.SGD","03130","LU1794554557.SGD","82846","BK0012","REDS","LU2148510915.USD","83188","LU1255011170.USD","LU1328615791.USD","07233","FRHC","BK0208","LU1146622755.USD","LU2495084118.USD","BK1564","LU1997244956.HKD","BK4127","LU1580142542.USD","BK1147","LU1064131003.USD","BK1516","BK1521","159982","BK0188","LU0405327148.USD","LU2289578879.USD","LU1720050803.USD","LU1064130708.USD","06030","LU0405327494.USD","02846","LU1781817850.SGD","LU2580892789.USD","LU1655091616.SGD","399300","02827","688065","BK0183","LU1997245177.USD","03188","IPOS","LU2580892862.HKD","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666280765","title":"9月11日凯赛生物现3笔大宗交易 机构净卖出4368.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666280765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666280765?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:38","pubTimestamp":1789119511,"startTime":"0","endTime":"0","summary":"证券之星消息，9月11日凯赛生物发生大宗交易，交易数据如下：近三个月该股共发生3笔大宗交易，合计成交1.76万手。该股近期无解禁股上市。截至2026年9月11日收盘，凯赛生物(688065)报收于39.86元，上涨0.66%，换手率2.06%，成交量12.04万手，成交额4.77亿元。该股近半年内有股东持股变动，合计净减持150.0万股，股东增减持明细如下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为60.18。本文数据来源于上海证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100038442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751121","title":"【私募调研记录】勤远投资调研凯赛生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666751121?lang=zh_cn&edition=full","pubTime":"2026-09-11 08:04","pubTimestamp":1789085089,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月10日披露的机构调研信息，知名私募勤远投资近期对1家上市公司进行了调研，相关名单如下：1）凯赛生物 调研纪要：2026年上半年，公司生物基聚酰胺系列实现营业收入1.08亿元，同比增长63%，毛利率0.57%。机构简介：上海勤远私募基金管理中心于2013年11月份成立于上海浦东，投资团队成员拥有良好的教育背景，以及丰富的实业创业和证券从业经验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026091100013906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597420","title":"股市必读：凯赛生物新发布《中信证券股份有限公司关于上海凯赛生物技术股份有限公司2026年半年度持续督导跟踪报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597420","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666597420?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:17","pubTimestamp":1789060628,"startTime":"0","endTime":"0","summary":"招商证券股份有限公司关于上海凯赛生物技术股份有限公司2026年持续督导定期现场检查报告招商证券现场检查确认公司治理结构健全，信息披露制度有效执行，独立性良好，无关联方资金占用；募集资金使用合规；未发现关联交易、对外担保和重大对外投资违规情形；公司经营正常，业务模式未发生重大变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1794554557.SGD","BK1516","LU1328615791.USD","LU1064130708.USD","LU1820825898.SGD","LU0405327148.USD","BK0188","LU2289578879.USD","LU1781817850.SGD","BK0208","LU1255011170.USD","LU2148510915.USD","LU1580142542.USD","688065","600030","BK0183","BK0028","BK1564","LU2580892862.HKD","LU1720050803.USD","LU0405327494.USD","LU1997245094.SGD","LU1146622755.USD","LU1064131003.USD","LU1997245177.USD","BK0196","BK1521","LU2495084118.USD","06030","BK0012","BK1147","LU1655091616.SGD","LU2580892789.USD","LU1997244956.HKD","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666759646","title":"凯赛生物：9月9日接受机构调研，兴业证券、浙商证券资管等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2666759646","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666759646?lang=zh_cn&edition=full","pubTime":"2026-09-10 21:10","pubTimestamp":1789045848,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月10日凯赛生物发布公告称公司于2026年9月9日接受机构调研，兴业证券、浙商证券资管、招银理财、勤远投资、银河证券参与。未来公司将继续围绕长链二元酸下游衍生物及新材料方向，审慎评估并购及投资机会。该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为60.18。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000040703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0028","BK0276","BK0208","601878","BK0012","601377","BK0188","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664880314","title":"凯赛生物被调出科创50指数 A股共募115亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2664880314","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664880314?lang=zh_cn&edition=full","pubTime":"2026-09-01 11:34","pubTimestamp":1788233643,"startTime":"0","endTime":"0","summary":"中国经济网北京9月1日讯 上海证券交易所与中证指数有限公司披露将调整科创50等指数样本，于2026年9月11日收市后生效，其中科创50指数更换5只样本，凯赛生物 被调出。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 凯赛生物上述2次募集资金合计114.87亿元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/01/20260901607569.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/01/20260901607569.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260901/32356125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["KCE","LU0405327494.USD","BK1521","07233","LU0405327148.USD","600030","IPOS","LU1064130708.USD","BK0028","83130","BK0276","BK4127","LU1720050803.USD","REDS","LU1655091616.SGD","BK1564","06030","LU1997245094.SGD","BK0208","03130","LU1580142542.USD","03188","82846","BK0183","LU1820825898.SGD","399300","159371","LU1146622755.USD","LU1997245177.USD","LU1064131003.USD","02827","02846","LU1997244956.HKD","LU2148510915.USD","LU2289578879.USD","LU2580892789.USD","BK0188","BK1516","LU2580892862.HKD","LU1794554557.SGD","LU1255011170.USD","LU1328615791.USD","83188","LU1781817850.SGD","LU2495084118.USD","159982","BK0012","FRHC","688065","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043339","title":"每周股票复盘：凯赛生物（688065）股东拟减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043339","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663043339?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:47","pubTimestamp":1788043629,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，凯赛生物报收于43.16元，较上周的45.27元下跌4.66%。本周，凯赛生物8月24日盘中最高价报45.4元。本周关注点公司公告汇总：持股5.57%股东计划减持不超过总股本2%的股份公司公告汇总关于持股5%以上股东减持股份计划的公告截至公告披露日，山西科技创新城投资开发有限公司持有上海凯赛生物技术股份有限公司40,139,958股，占总股本的5.57%，股份来源于IPO前及资本公积转增。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000003568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662788498","title":"破发股凯赛生物股东拟减持 A股募115亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2662788498","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662788498?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:07","pubTimestamp":1787627233,"startTime":"0","endTime":"0","summary":"中国经济网北京8月25日讯 凯赛生物 昨日晚间披露《关于持股5%以上股东减持股份计划的公告》。山西科创城投减持计划拟自公告披露之日起15个交易日后的3个月内进行，减持价格将参考市场价格。 截至公告披露之日，山西科创城投持有凯赛生物40,139,958股股份，占凯赛生物总股本的5.57%。 截至2026年6月30日，山西科创城投为凯赛生物第四大股东。 凯赛生物上述2次募集资金合计114.87亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260825/32345897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4127","LU1794554557.SGD","BK1516","83188","LU1328615791.USD","LU1064130708.USD","IPOS","LU0405327148.USD","BK0188","LU2289578879.USD","LU1781817850.SGD","82846","07233","REDS","BK0208","LU1255011170.USD","LU2148510915.USD","FRHC","688065","399300","600030","LU1580142542.USD","02846","BK0183","KCE","BK0028","BK1564","LU2580892862.HKD","83130","LU1720050803.USD","LU0405327494.USD","LU1997245094.SGD","LU1064131003.USD","LU1997245177.USD","03188","BK0196","BK1521","LU2495084118.USD","06030","BK0012","BK1147","LU1655091616.SGD","159982","LU2580892789.USD","LU1997244956.HKD","03130","BK0276","02827"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827441","title":"凯赛生物（688065）披露持股5%以上股东减持股份计划公告，8月24日股价下跌2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827441","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661827441?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:08","pubTimestamp":1787580481,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，凯赛生物报收于44.0元，较前一交易日下跌2.81%，最新总市值为317.37亿元。该股当日开盘45.18元，最高45.4元，最低43.56元，成交额达2.43亿元，换手率为0.94%。近日，凯赛生物发布《关于持股5%以上股东减持股份计划的公告》。减持价格将参考市场价格，减持期间为2026年9月15日至2026年12月14日。本次减持计划符合相关法律法规规定，实施存在不确定性，不会导致公司控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400036807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174533391","title":"凯赛生物公告：股东拟于9月15日至12月14日期间减持不超2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1174533391","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174533391?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:27","pubTimestamp":1787567229,"startTime":"0","endTime":"0","summary":"凯赛生物披露，其股东已明确表态，计划在9月15日至12月14日这一时间窗口内，对公司股份进行减持操作。据悉，此番减持规模上限为公司总股本的2%。此举无疑引发市场关注，投资者对此举背后的动因及潜在影响议论纷纷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661521124","title":"每周股票复盘：凯赛生物（688065）Q2净利增20.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661521124","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661521124?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:32","pubTimestamp":1787423531,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，凯赛生物报收于45.27元，较上周的46.6元下跌2.85%。本周，凯赛生物8月20日盘中最高价报48.16元。本周关注点来自业绩披露要点：2026年第二季度归母净利润2.07亿元，同比上升20.56%。《2026年度提质增效重回报专项行动方案》半年度评估报告显示，公司实现营收190,018万元，同比增长13.73%；归母净利润37,273万元，同比增长20.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661231257","title":"股市必读：凯赛生物中报 - 第二季度单季净利润同比增长20.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661231257","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661231257?lang=zh_cn&edition=full","pubTime":"2026-08-21 02:56","pubTimestamp":1787252171,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，凯赛生物报收于46.29元，上涨0.09%，换手率1.05%，成交量6.14万手，成交额2.89亿元。业绩披露要点：2026年上半年主营收入19.0亿元，归母净利润3.73亿元，第二季度单季归母净利润2.07亿元。公司公告汇总：董事会审议通过作废2022年限制性股票激励计划中74.123万股已授予尚未归属的限制性股票，并确认2019年及2023年两期募集资金均已使用完毕、专户注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100002092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790645447666,"stockEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.1161},{"period":"3month","weight":-0.1946},{"period":"6month","weight":-0.2306},{"period":"1year","weight":-0.2512},{"period":"ytd","weight":-0.2261}],"compareEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.0325},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0316},{"period":"1year","weight":-0.0012},{"period":"ytd","weight":-0.0366}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"19123人(较上一季度增加3.24%)","perCapita":"30506股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC9-DC18）及其衍生产品、生物基戊二胺、系列生物基聚酰胺树脂及其改性产品、生物基连续纤维热塑型复合材料（Bio-PPACFRT）、生物基哌啶。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}